Previous Article | Next Article 
Infection and Immunity, December 1999, p. 6611-6618, Vol. 67, No. 12
0019-9567/99/$04.00+0
Production of Tumor Necrosis Factor Alpha in Human
T Lymphocytes by Staphylococcal Enterotoxin B Correlates with
Toxin-Induced Proliferation and Is Regulated through Protein
Kinase C
Zhengyin
Yan,1,2,
David C. H.
Yang,1
Roger
Neill,2 and
Marti
Jett1,2,*
Chemistry Department, Georgetown University,
Washington, D.C. 20056,1 and Department
of Molecular Pathology, Walter Reed Army Institute of Research,
Washington, D.C. 203072
Received 21 April 1999/Returned for modification 14 June
1999/Accepted 16 August 1999
 |
ABSTRACT |
The superantigen staphylococcal enterotoxin B (SEB) simultaneously
binds both the major histocompatibility complex (MHC) class II receptor
on monocytes and the T-cell receptor (TCR) on T lymphocytes, resulting
in a range of cell responses including induction of tumor necrosis
factor alpha (TNF-
). In this study, we have used mixed cultures of
human peripheral blood monocytes and lymphocytes to investigate
biochemical events controlling SEB induction of TNF-
. TNF-
production induced by SEB in mixed cultures is more closely associated
with T cells than with monocytes: (i) a TCR-binding-site mutant of SEB
(N23F) is less active in TNF-
induction than an MHC class II
receptor-binding-site mutant (F44R), and (ii) flow cytometric analysis
indicated that SEB induced TNF-
production in T cells but not in
monocytes. Pretreatment of cells with inhibitors of signal transduction
pathways was employed to further define events in SEB-induced TNF-
production. Neither protein kinase A inhibitors nor two protein
tyrosine kinase inhibitors altered SEB-induced TNF-
production. In
contrast, SEB induced protein kinase C (PKC) translocation, and
pretreatment of cultures with inhibitors of PKC blocked TNF-
induction. Alteration of levels of diacylglycerol (DAG), an activator
of PKC, by treatment with inhibitors of phospholipase C or DAG kinase
also altered SEB-induced TNF-
production. These data suggest that
PKC activation plays a critical role in SEB-induced TNF-
production
in human T cells.
 |
INTRODUCTION |
Originally characterized for their
ability to induce the emesis and diarrhea associated with food
poisoning (5), staphylococcal enterotoxins (SEs) also
exhibit biological activities that can lead to lethal shock (29,
39). SEs constitute a group of nine serologically distinct (types
A to E and G to J) proteins that have sequence and structural
homologies and are members of the functionally related family of
pyrogenic exotoxins (8) that includes streptococcal
pyrogenic exotoxin and toxic shock syndrome toxin 1 (TSST-1).
These toxins function as superantigens (29), exhibiting the
ability to activate large numbers of T cells. This property is a result
of the toxin's bifunctional interaction with both the major
histocompatibility complex (MHC) class II receptors on
antigen-presenting cells such as monocytes and the T-cell receptor of T
lymphocytes expressing specific V
chains to which an individual toxin binds (22). For several of the toxins, including
staphylococcal enterotoxin B (SEB), the structural domains and amino
acid residues participating in these receptor interactions have been
identified and three-dimensional structural analyses of the binding of
toxin to the MHC class II receptor and T-cell receptor have been
described elsewhere (19, 23, 25).
Binding of cell surface receptors leads to activation of gene
expression through enlistment of signal transduction pathways. These
pathways consist of a cascade of biochemical events that can include
activation of a variety of kinases including protein tyrosine kinases
(PTKs), protein kinase C (PKC), or protein kinase A (PKA). These
kinases in turn modify other factors that control individual gene
expression. One or more of these kinases may participate in controlling
a gene's expression. Ligand engagement of MHC class II receptors and
T-cell receptors activates such signal transduction events (9,
18).
The superantigen activity of SEs results in induction of T-cell
proliferation and in synthesis of a variety of cytokines including interleukin-1 (IL-1), IL-2, IL-6, gamma interferon, and tumor necrosis
factor alpha (TNF-
) (24). It is the massive release of
such cytokines that is thought to contribute to the immune dysfunction
characteristic of superantigen toxicity including lethal shock
(29). TNF-
is an important cofactor in endotoxic shock
(13). It mediates SEB-induced lethality in mouse models that
involve both MHC class II and T-cell interactions (28, 33,
46).
TNF-
induced by superantigen can be produced by both monocytes and T
cells (1, 15, 30). Previous studies have examined the
induction of TNF-
by SEA, SEB, or TSST-1 (15, 30, 38, 42,
43). In this study, we wished to characterize the induction of
TNF-
by SEB in mixed cultures of human monocytes in the presence of
lymphocytes. We wanted to determine which cell types produce TNF-
under these culture conditions and which signal transduction pathways
are involved. In order to examine the induction of TNF-
by SEB, we
have employed receptor-binding mutants of SEB, immunodetection and
FACScan analysis of TNF-
-producing cells, and inhibitors of signal
transduction pathways.
 |
MATERIALS AND METHODS |
Reagents.
SEB, lot 14-30, was obtained from the U.S. Army
Research Institute of Infectious Diseases, Frederick, Md. SEB mutants
F44R and N23F were constructed by site-directed mutagenesis and
purified as described previously (35). The inhibitors
genistein, H7, sphingosine, chelerythrine chloride, HA1004, H89,
U73122, R59949, and tyrophostin 23 were purchased from Biomol (Plymouth
Meeting, Pa.). Phorbol 12-myristate 13-acetate (PMA) and the inhibitor tyrophostin AG1288 were obtained from Calbiochem (La Jolla, Calif.). Fluorescein isothiocyanate (FITC)-mouse immunoglobulin G1,
CD3(Leu-4)-phycoerythrin (PE), and CD14(Leu-M3)-PE were from Becton
Dickinson (Mansfield, Mass.). FITC-anti-human TNF-
monoclonal
antibody (MAb) and monensin were from PharMingen (San Diego, Calif.).
Preparation of human monocytes and lymphocytes.
Peripheral
blood mononuclear cells were prepared from leukopacks from normal
donors by centrifugation over lymphocyte separation medium as described
previously (21). Monocytes and lymphocytes were then further
purified from these preparations by counterflow centrifugation-elutriation with pyrogen-free Ca2+- and
Mg2+-free phosphate-buffered saline as the eluant. This
method resulted in cell preparations containing 95 to 99% of the
indicated cell type with viability greater than 95%. Unless indicated
otherwise, monocytes and lymphocytes were mixed in a 1:4 ratio prior to
use. That ratio had been found in earlier studies (21) to
provide near-maximal proliferative response. For all experiments, cells were cultured in a humidified atmosphere (5% CO2) in RPMI
1640 medium containing glutamine and supplemented with 10% human AB serum.
Proliferation in cultures of human lymphocytes and monocytes in
response to SEB.
The experiments were carried out as described
previously (21). Briefly, monocytes (0.5 × 105 cells per well) and lymphocytes (2.0 × 105 cells per well) were mixed in medium and plated in
96-well plates. Native SEB or SEB mutant proteins were added to
appropriate wells (total volume, 200 µl), and the cultures were
incubated for 72 h. One microcurie of
[3H-methyl]thymidine per well was incubated with the
cells for the final 18 h. The cells were collected on filter
plates by using a multiwell harvesting device. Microscint-O liquid
scintillation cocktail (Packard Instruments, Meriden, Conn.) was added
to dried filter plates, and radioactivity was determined with the Top
Count scintillation counter (Packard Instruments). Six replicates of each sample were tested in each experiment, and each experiment was
repeated at least three times. Examination of proliferation in the
presence of various inhibitors of proliferation was carried out by
adding the inhibitors to the appropriate wells 30 min before addition
of SEB at a final concentration of 50 ng/ml. The remainder of the assay
was carried out as described above.
TNF-
production in response to SEB or PMA.
Monocytes and
lymphocytes were mixed in the ratio 1:4, unless indicated otherwise.
The cell mixture was plated at a density of 106 cells/well
in four replicates in 24-well plates. Inhibitors were preincubated with
the cells for 60 min, after which time SEB, PMA, or medium was added to
individual wells to bring the total volume to 1 ml. Cells were cultured
for 20 h. Culture medium was obtained from four replicates, and
each was centrifuged to remove any precipitates. Supernatant solutions
were used for TNF-
analysis. The amount of TNF-
released in
culture medium was determined by using a commercial human TNF-
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Rochester,
Minn.) according to the manufacturer's instructions.
Protein assay.
Protein concentrations of samples were
determined by the Bio-Rad protein assay (Hercules, Calif.) according to
the manufacturer's instructions.
PKC assay.
Monocytes and lymphocytes were mixed in a ratio
of 1:4 in medium. A total of 2 × 107 mixed cells were
incubated in microcentrifuge tubes in the presence of 100 ng of SEB per
ml. At the times indicated, cells were collected by centrifugation,
washed once with ice-cold phosphate-buffered saline, and then
resuspended in 0.5 ml of ice-cold lysing buffer (20 mM Tris-HCl [pH
7.5], 5 mM EDTA, 10 mM EGTA, 0.3% [wt/vol] 2-mercaptoethanol, 10 mM
benzamidine, and 1 mM phenylmethylsulfonyl fluoride). The cells were
lysed by sonication on ice for 30 s. Cell lysates were centrifuged
at 100,000 × g for 60 min at 4°C, and supernatant
solutions were collected as cytosolic fractions. The pellets were
resonicated for 20 s in 0.5 ml of lysing buffer containing 1%
Triton X-100 and then rocked gently for 60 min in an ice bath. After
centrifugation at 50,000 × g, supernatant solutions were collected as solubilized membrane fractions. PKC activity was
measured in duplicate with a nonradioactive protein kinase assay kit
(Calbiochem). A dilution series of PKC preparations from rat brain
(Calbiochem) was used in each assay to produce a standard curve for use
in determining relative PKC activity in the test samples. PKC activity
was expressed as units per microgram of protein in each fraction.
PTK assay.
A total of 107 premixed cells (1:4)
were incubated with 100 ng of SEB per ml for the time indicated. After
being washed once with phosphate-buffered saline containing 1 mM sodium
vanadate, cells were lysed on ice for 5 min in 0.5 ml of RIPA buffer
(50 mM Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM dithiothreitol, 0.5 mM EDTA, 1.0% Nonidet P-40, 0.5% sodium deoxycholate, 0.15% sodium dodecyl sulfate, 100 µg of phenylmethylsulfonyl fluoride per ml, 1 µg of aprotinin per ml, 2 µg of leupeptin per ml, and 100 µM sodium vanadate), followed by homogenization with 10 10-s bursts on a
microsonicator. The homogenates were centrifuged at 10,000 × g for 10 min at 4°C, and supernatant solutions were collected as total protein extracts. PTK activity was determined with a nonradioactive tyrosine kinase assay kit (Boehringer Mannheim, Indianapolis, Ind.), with two different biotin-labeled peptides as PTK
substrates. Each peptide is specific for different classes of PTK.
Total PTK activity was measured by using a mixture of equal amounts of
both peptides as substrates in the PTK assay. A series of diluted
prephosphorylated peptides (provided with the kit) were used as
standards to calculate the amount of phosphopeptide in PTK reactions.
PTK activity was expressed as picomoles of phosphopeptide per minute
per microgram of protein.
FACScan analysis of TNF-
expression.
FACScan flow
cytometry in combination with an intracellular cytokine staining method
(14) was employed to analyze TNF-
gene expression in
situ. Cell permeabilization was achieved by using the cell
fixation-permeabilization kit obtained from PharMingen. Purified
monocytes and lymphocytes were mixed in a ratio of 1:1. A total of
106 mixed cells in medium were added to 15-ml tubes and
incubated with or without 100 ng of SEB per ml for 6 h at 37°C
in the presence of 2 µM protein transport inhibitor monensin. Cells
were harvested by centrifugation at 500 × g for 7 min,
resuspended in 1 ml of staining buffer containing 0.25% inactivated
mouse serum, and then incubated at 4°C for 15 min to block Fc
receptors. Samples were divided into two test tubes, and fluorescently
tagged reagents were added to identify cell type by using either 20 µl of the anti-T-lymphocyte antibody CD3(Leu-4)-PE or the
antimonocyte antibody CD14(Leu-M3)-PE to stain the cells for 30 min at
4°C in the dark. After being washed twice with 1 ml of staining
buffer, cells were resuspended in 250 µl of Cytofix/Cytoperm solution
followed by incubation in the dark at 4°C for 20 min. The fixed and
permeabilized cells were washed twice with 1 ml of Perm/Wash solution
and thoroughly resuspended in 50 µl of Perm/Wash solution containing
0.5 µg of FITC-anti-TNF-
MAb, followed by incubation for 30 min
at 4°C in the dark. To establish the degree of nonspecific binding,
control and SEB-stimulated cells were stained with 0.5 µg of
FITC-mouse immunoglobulin G1. Stained cells were washed twice with 1 ml
of Perm/Wash solution and resuspended in 1 ml of staining buffer. Samples were analyzed on a FACScan flow cytometer (Becton Dickinson). The typical forward and side scatter gates for lymphocytes and monocytes (with cells stained with CD3, CD14, or the nonspecific stain)
were set respectively to exclude any dead cells. Within this gate,
10,000 events were acquired per sample. Two-parameter dot plots
demonstrating cytokine and cell marker staining were generated by using
the LYSIS II software (Becton Dickinson), and quadrant statistics were
set on the basis of staining controls.
 |
RESULTS |
Induction of TNF-
by SEB.
In order to study events involved
in the production of TNF-
by SEB, we first examined parameters
controlling induction in mixed cultures of human lymphocytes and
monocytes. Initial time course experiments indicated that increased
TNF-
levels in culture fluids began 4 h after addition of SEB,
reached maximal levels by 17 h, and remained constant through
24 h. For subsequent experiments, levels of production of TNF-
were measured at 20 h following addition of toxin, except where
indicated. In previous studies, a ratio of monocytes to lymphocytes of
1:4 in mixed culture was optimal for SEB induction of proliferation of
lymphocytes (21). Similarly, we found that levels of TNF-
induced by SEB varied with different combinations of monocytes and
lymphocytes (Fig. 1). The maximal level
for SEB induction of TNF-
occurred at a 1:4 ratio of monocytes to
lymphocytes. This cell ratio was employed in all subsequent
experiments, except where indicated.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Effect of cell ratio on induction of TNF- by SEB.
Purified monocytes and lymphocytes were mixed in different cell ratios
and plated in 24-well plates in four replicates at a density of
106 cells/well. Cells were cultured for 20 h in the
presence of 10 (filled bars) and 100 (striped bars) ng of SEB per ml.
Culture media were collected and assayed in duplicate for TNF-
production.
|
|
Dependence on mixed culture for SEB induction of TNF-
.
We
wished to determine whether TNF-
induction by SEB requires mixed
cultures of lymphocytes and monocytes or can occur with either cell
type alone. For this purpose, lymphocytes, monocytes, or mixed cells
were incubated with increasing doses of SEB (Fig. 2A). In mixed culture, a dose of SEB as
low as 10 ng/ml was sufficient to induce 50-fold-greater amounts of
TNF-
(500 pg/ml) compared to the untreated negative control (~10
pg/ml). TNF-
production reached a plateau at 100 ng of SEB per ml.
This concentration was used as our standard in subsequent experiments.
In the absence of monocytes, SEB-treated lymphocytes responded with
increased levels of TNF-
. However, the response was significantly
less than that exhibited by mixed culture even at a high dose of toxin (17% of response of mixed cells at 1,000 ng of SEB per ml).

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 2.
Dependence on concentration of SEB for TNF-
induction. Cells were plated in four replicates at a density of
106/well and then cultured for 20 h in the presence of
different concentrations of SEB. Culture media were collected and
assayed in duplicate for TNF- production. (A) Monocytes ( ),
lymphocytes ( ), and mixed cells ( ). (B) Monocytes alone in the
presence of high concentrations of SEB.
|
|
In contrast, monocytes alone did not secrete significant amounts above
control of TNF-
at concentrations of SEB ranging from 10 to 1,000 ng/ml (Fig. 2A). Previous studies had reported that SEB activated
TNF-
gene expression in human monocytes (30, 38) and in
the human monocytic cell line THP-1 in the absence of T lymphocytes
(43). However, the concentrations of toxin used in those
studies (1 to 10 µg/ml) were greater than our standard dose of 100 ng/ml. Therefore, we examined the response of monocytes exposed to
higher concentrations of SEB (1 to 20 µg/ml). Although high doses of
SEB did stimulate TNF-
production in monocytes alone (Fig. 2B), the
levels of TNF-
induced by the highest dose of SEB tested (20 µg/ml) were only 18% of those seen in mixed culture exposed to 100 ng of SEB per ml.
TNF-
induction by SEB mutants.
Mutation analysis of SEB had
revealed that residue phenylalanine-44 (F44) is important to the
binding of SEB to the MHC class II receptor on monocytes and that
residue asparagine-23 (N23) is critical for interaction with the T-cell
receptor (23). To examine the role which binding of SEB to
MHC class II receptor or T-cell receptor plays in TNF-
induction, we
compared levels of TNF-
induction by native SEB and by two amino
acid substitution mutants that we constructed. Mutant F44R contains an
arginine substitution for F44 and mutant N23F contains a phenylalanine substitution for N23. At SEB concentrations of 25 ng/ml or less, neither mutant induced a significant TNF-
response (Fig.
3A). However, at a higher dose (100 ng/ml) F44R activity approached 77% of that of the native toxin
response, whereas N23F exhibited only 28% of native SEB activity.
Similar behavior was exhibited by these mutant toxins when examined in
a proliferation assay. As in the TNF-
response, both mutant toxins
had greatly reduced activity at 25 ng/ml or less (Fig. 3B). At 50 ng/ml, F44R had 62% of the proliferation activity of SEB while N23F
was only 26% as active. At 100 ng/ml, however, N23F had 33% of the
native toxin activity whereas the response of F44R (98%) was
comparable to that of SEB. These results suggested that activation of
lymphocytes is critical for SEB induction of TNF-
.

View larger version (19K):
[in this window]
[in a new window]
|
FIG. 3.
Comparison of SEB and SEB mutant proteins F44R and N23F
for stimulation of TNF- production (A) and proliferation (B).
Symbols: , SEB; and , SEB mutants F44R and N23F,
respectively. (A) Monocytes and lymphocytes (1:4 ratio) were plated in
four replicates and cultured for 20 h in the presence of varying
concentrations of toxin. Culture media were collected, and TNF-
production was analyzed in duplicate. Statistical analysis
(t test) of significant differences compared to native SEB
showed P < 0.001 at the concentrations 25 to 100 µg/ml for mutant protein N23F and at 25 and 50 µg/ml for mutant
protein F44R. (B) Incorporation of [3H-methyl]thymidine
in mixed culture was determined after exposure to toxin for 72 h.
The data are averages of three experiments done in replicates of six.
Statistical analysis (t test) of significant differences
compared to native SEB showed P < 0.001 at the
concentrations 6 to 100 ng/ml for mutant protein N23F and at 6 to 50 ng/ml for mutant protein F44R.
|
|
FACScan analysis of TNF-
production.
As another approach to
identifying the cell type most responsible for TNF-
production in
response to SEB, we used FACScan analysis for measurement of TNF-
synthesis in situ in specific cell types. Monocytes and lymphocytes,
mixed in a ratio of 1:1, were incubated for 6 h with or without
SEB (100 ng/ml) in the presence of the protein transport inhibitor
monensin so that TNF-
molecules would accumulate in the Golgi
complex. After cell fixation and permeabilization, FITC-TNF-
MAb
was used for the intracellular staining of TNF-
. As shown in
two-parameter dot plots (Fig. 4A and B),
SEB stimulation resulted in a significantly large proportion (9.7%) of
T lymphocytes (CD3 positive, x axis) producing TNF-
(y axis) compared to that of nonstimulated cells (0.58%).
SEB treatment (Fig. 4C and D) also increased the numbers (0.89%) of monocytes (CD14 positive, x axis) producing TNF-
compared
to the nonstimulated control (0.04%). However, the overall numbers of
TNF-
-positive monocytes were more than 10-fold lower than the
numbers of TNF-
-positive lymphocytes (0.89 versus 9.7%) induced by
SEB. This result indicates that lymphocytes and not monocytes are the
predominant producers of TNF-
in response to SEB in a mixed culture
of human cells.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 4.
FACScan analysis of TNF- expression in monocytes and
lymphocytes. Monocytes and lymphocytes (5 × 105 each)
were mixed and incubated for 6 h with 100 ng of SEB per ml in the
presence of 2 µM monensin. Samples were fixed and then permeabilized
and stained with cell-type-specific antibody and analyzed on a FACScan
flow cytometer. Negative controls (A and C) were without SEB. Samples
were stained with anti-CD3 or anti-CD14 antisera to identify the
following: lymphocytes (A), lymphocytes plus SEB (B), monocytes (C),
and monocytes plus SEB (D).
|
|
Inhibition of SEB-induced TNF-
production by PKC
inhibitors.
We wished to identify the signal transduction pathways
that may be involved in converting the cell surface receptor binding of
SEB into the induction of TNF-
. For this purpose, we employed inhibitors of different kinases involved in signal transduction to
determine which, if any, blocked SEB-induced TNF-
production. We
first examined the role of PKC in the response by treating mixed
cultures of monocytes and lymphocytes for 60 min before SEB stimulation
with increasing doses of three specific PKC inhibitors, H7
(20), sphingosine (17), and chelerythrine
(11). As shown in Fig. 5,
treatment of cells with PKC inhibitors resulted in a substantial
reduction in TNF-
secretion, and the inhibitory effect occurred in a
dose-dependent manner. Trypan blue exclusion studies indicated no loss
of cell viability in response to these inhibitors at tested
concentrations, indicating that the cells were not obviously damaged by
use of the inhibitors. These inhibitors also blocked SEB-induced cell
proliferation (data not shown).

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 5.
Effect of PKC inhibitors on induction of TNF- by SEB.
Monocytes and lymphocytes were plated in four replicates; incubated
with either sphingosine ( ), chelerythrine ( ), or H7 ( ) for 60 min followed by stimulation with 100 ng of SEB per ml for 20 h;
and then analyzed for TNF- . Statistical analysis (t test)
of significant differences compared to SEB alone showed P < 0.05 at the concentrations 10 and 20 µM for H7 and at 20 µM
only for the other two inhibitors.
|
|
PKC translocation induced by SEB.
We next examined the ability
of SEB to activate PKC by inducing its translocation from cytosolic to
membrane fractions in mixed cultures of monocytes and lymphocytes.
Incubation of cells with 100 ng of SEB per ml resulted in a significant
increase in membrane-associated PKC activity and a concomitant decrease
in cytosol-associated PKC activity (Fig.
6). This translocation of PKC was
observed as early as 15 min after SEB exposure.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of translocation of PKC by SEB. A total of
2 × 107 monocytes plus lymphocytes (1:4 ratio) were
stimulated with 100 ng of SEB per ml for the time indicated. Cytosolic
( ) and membrane ( ) fractions were prepared as described in the
text. The activity is expressed as units per microgram of protein.
|
|
Inhibition of induction of TNF-
by PLC inhibitor.
Phospholipase C (PLC) plays a central role in the activation of PKC
through its production of diacylglycerol (DAG), an activator of PKC
(36). Inhibition of PLC may indirectly inhibit PKC and thus
effect TNF-
induction. To investigate the involvement of PLC in
TNF-
induction, we examined the effect of U73122, a PLC inhibitor
(7), on TNF-
production induced by SEB. Cells were incubated with different doses of the inhibitor for 60 min to block the
effect of PLC and then stimulated with 100 ng of SEB per ml. Results
shown in Fig. 7 indicate that
pretreatment of cells with the PLC inhibitor U73122 caused a
significant reduction of TNF-
production, and this inhibitory effect
appears to be dose dependent.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 7.
Inhibition of SEB-induced TNF- production by PLC
inhibitor U73122. Monocytes and lymphocytes (1:4 ratio) were plated in
four replicates and incubated with different doses of the PLC inhibitor
U73122 for 60 min followed by stimulation with 100 ng of SEB per ml.
Media were collected and analyzed in duplicate for TNF- production.
Statistical analysis (t test) of significant differences
compared to native SEB showed P < 0.05 for all
concentrations of inhibitor used.
|
|
Stimulation of SEB-induced TNF-
production by a DAG kinase
inhibitor.
To explore the possibility that DAG plays a role in
TNF-
induction by SEB through its activation of PKC, we studied the
effect of the DAG kinase inhibitor, R59949, on SEB-induced TNF-
production. R59949 elevates intracellular DAG levels by blocking one of
DAG's degradation pathways (12). If DAG plays a role in
SEB-induced TNF-
production, it is expected that preincubation of
cells with R59949, inhibiting DAG degradation, should result in an
increase of TNF-
synthesis. SEB was used at 10 ng/ml in order to be
in a low-linear range of TNF-
production by SEB, so that increases in its production could be observed. As shown in Table
1, pretreatment of cells with R59949 did
increase SEB-induced TNF-
production (30%).
The effect of PKA and PTK inhibitors on SEB-induced TNF-
production and proliferation.
We used other specific inhibitors to
determine if other kinase activities regulated SEB-stimulated TNF-
production or proliferation of lymphocytes. To determine whether PKA
was involved in SEB-induced TNF-
production, cells were incubated
with two PKA-specific inhibitors, HA1004 (45) and H89
(2), for 60 min, followed by SEB stimulation. As shown in
Table 2, treatment of cells with PKA
inhibitors did not cause significant decreases either in TNF-
production or in proliferation.
In order to assess the role of PTK, cells were treated with three PTK
inhibitors for 60 min prior to SEB stimulation. It was observed
that both tyrophostin 23 and AG1288 were unable to block either
TNF-
production or proliferation (Table 2). However, a less-specific
PTK inhibitor, genistein, suppressed both TNF-
production and
proliferation by approximately 50% (Table 2). Genistein has been shown
elsewhere to inhibit PKC activity (16, 27). Since the data
presented here suggest that PKC is involved in TNF-
gene expression,
inhibition of SEB-induced TNF-
could result from the nonspecific
effects of this inhibitor. To address this possibility, we studied the
effect of genistein on TNF-
induction by PMA, a well-known PKC
activator (3). As shown in Table
3, like PKC inhibitors H7 and
sphingosine, genistein was able to block PMA-induced TNF-
secretion,
suggesting that its inhibitory effect on SEB-induced TNF-
production
is through its effect on PKC and not PTK.
The effects of SEB on total PTK activity.
We measured the
effects of SEB on total PTK activity, in a further attempt to resolve
the contradictory data obtained from our PTK inhibitor studies
examining the role of PTK in TNF-
production induced by SEB. Mixed
monocyte and lymphocyte cultures were stimulated with 100 ng of SEB per
ml for the time indicated, and total PTK activity in cell lysates was
determined (Fig. 8). Total PTK activity did not significantly increase after SEB stimulation.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 8.
Total PTK in lysates in SEB-treated
monocyte-plus-lymphocyte cultures. A total of 107 monocytes
plus lymphocytes (1:4 ratio) were stimulated with 100 ng of SEB per ml
for the time indicated. Total PTK activity in whole-cell lysates is
expressed as picomoles of phosphopeptide per minute per microgram of
protein. These data do not represent significant differences from
controls.
|
|
 |
DISCUSSION |
We have attempted to determine the cells primarily involved in
SEB-induced TNF-
production in mixtures of human monocytes and
lymphocytes and to identify signal transduction pathways mediating this
event. Our results indicate that, at low concentrations of SEB (100 ng/ml), efficient production of TNF-
requires the presence of both
lymphocytes and monocytes and that, in such mixed cultures, lymphocytes
are the predominant producer of TNF-
. Our results also suggest that
PKC plays an important role in SEB-induced TNF-
production.
In a mixed culture of monocytes and lymphocytes, SEB induced
significant amounts of TNF-
(Fig. 2A). At concentrations as low as
10 ng/ml, SEB induced levels of TNF-
50-fold greater than those in
untreated cells. In contrast, lymphocytes alone had a much lower
response, producing at most only 17% of the amount found in mixed
culture at 1,000 ng/ml. This limited response may be attributable to
the presence of low levels of antigen-presenting cells in our
lymphocyte preparations. Unlike lymphocytes alone, monocytes alone did
not secrete significant amounts of TNF-
at SEB concentrations of 10 to 1,000 ng/ml (Fig. 2A). Thus, both cell types are required for an
efficient response. A similar requirement for the presence of both
monocytes and lymphocytes together has been reported elsewhere for
induction of TNF-
by SEA (15) and TSST-1 (42).
Moreover, incubation of monocytic cell line THP-1 with SEB did not
activate TNF-
gene expression (31). Our results (Fig. 2B)
and those of others (43) indicate that, at high
concentrations of SEB (1 to 10 µg/ml), monocytes do express increased
levels of TNF-
but at amounts that are much lower than those found
in mixed culture.
SEB-induced TNF-
production is mediated by both MHC class II
receptors on monocytes and T-cell receptors on lymphocytes (4, 33). Mutant SEB proteins with an amino acid substitution in either the toxin's MHC class II receptor binding site (F44R) or the
T-cell-receptor binding site (N23F) exhibited substantial reductions in
the ability to induce TNF-
(Fig. 3A) as well as proliferation (Fig.
3B) at low concentrations of mutant toxin. At higher concentrations,
both mutants exhibited activity. However, the T-cell-receptor-binding
mutant was still significantly less active than either native toxin or
the MHC class II-receptor-binding mutant, for induction either of
TNF-
or of proliferation. This result suggests a more important role
for T cells in SEB-induced TNF-
production.
Although it is well defined that SE toxin-reactive T cells are
responsible for the production of cytokines such as IL-2 and gamma
interferon, the cell type which secretes TNF-
after SEB stimulation
is less certain (32), especially when mixed populations consisting of monocytes and lymphocytes are used. FACScan analysis (Fig. 4) of SEB-treated mixed culture (1:1 ratio) clearly indicates that by far the greater number of TNF-
-producing cells are T cells
(9.7% of lymphocytes) rather than monocytes (0.89% of monocytes). That only 9.7% of T cells are TNF-
positive, when treated with a
concentration (100 ng/ml) of SEB that induces maximal levels of
TNF-
, may reflect the fact that SEB interacts only with certain subsets of T lymphocytes bearing specific V
regions (22).
Therefore, not all T lymphocytes would be expected to be induced by
SEB. Fischer et al. (15) found equal numbers of monocytes
and lymphocytes producing TNF-
when treated with
nanogram-per-milliliter amounts of SEA. This ratio is much higher than
that seen in this study with SEB and may reflect the specific ability
of SEA to activate monocytes in the absence of lymphocytes
(31). In any case, our in vitro results are consistent with
in vivo observations, which indicated that T cells are the predominant
TNF-
-positive cells in tissues from SEB-challenged mice (6,
26).
By using various inhibitors, we have attempted to identify signal
transduction pathways that are involved in mediating SEB-induced TNF-
production in mixed cultures of human monocytes and
lymphocytes. We examined the effect of inhibitors for the PKA, PTK, and
PKC pathways on SEB-induced TNF-
production and on proliferation (Table 2 and Fig. 5). The PKA inhibitors HA1004 and H89 failed to block
SEB-induced TNF-
production (Table 2), indicating that the PKA
pathway is not involved. A similar lack of involvment of PKA in toxin
induction of TNF-
was reported for a TSST-1-treated mixed culture of
human monocytes and lymphocytes (41).
Inhibitor studies indicated that PKC was involved in TSST-1 induction
of TNF-
in cultures of human monocytes and lymphocytes (41) and in SEB-induced IL-1
production in human
monocytes (30, 38). We addressed the possible role of PKC in
SEB induction of TNF-
by using inhibitors that suppress PKC activity
or indirectly activate this enzyme. Three inhibitors of PKC activity,
H7, chelerythrine, and sphingosine, each suppressed SEB-induced TNF-
production in a mixed culture of monocytes and lymphocytes (Fig. 5).
PKC is activated by DAG, and we reasoned that if we decreased DAG levels by inhibiting PLC activity or increased DAG by inhibiting its
degradation by DAG kinase we could alter SEB-induced TNF-
production. Indeed, the PLC inhibitor U73211 inhibited SEB-induced TNF-
(Fig. 7), whereas the DAG kinase inhibitor R59949 increased SEB-induced TNF-
(Table 1). In addition, we found that SEB induced translocation (i.e., activation) of PKC in mixed culture (Fig. 6) and
that PMA, a DAG-like activator of PKC, also induces TNF-
(Table 3).
Activation of PKC also occurred following TSST-1 or SEB treatment of
purified human monocytes (38, 44) and TSST-1 treatment of
human peripheral blood mononuclear cells (10). PMA induced
IL-1
and TNF-
in purified human monocytes (30). These
results strongly support a role for PKC in mediating SEB induction of
TNF-
.
Several studies suggested that PTK also might be involved in TNF-
induction by SE. Binding of SEs to the MHC class II receptors of
purified monocytes was reported to lead to activation of src-related PTK (34). Inhibitors of PTK blocked induction of IL-1
in
TSST-1-treated THP-1 cells (40) and in SEB-treated purified
human monocytes (30). In these studies,
microgram-per-milliliter levels of toxin were used. Moreover, PTK
inhibitors blocked lipopolysaccharide-induced TNF-
production
(37). However, we found no effect on SEB-induced TNF-
production by two PTK inhibitors, tyrophostin 23 and AG1288 (Table 2).
We also saw no effect of treatment of a mixed culture with SEB on total
PTK activity. A third PKA inhibitor that we tested, genistein, did
block both SEB-induced TNF-
production and proliferation by about
50% (Table 2). However, at the concentration used in this study (20 µM), genistein has been reported to inhibit PKC as well
(16). We found that genistein inhibited induction of TNF-
by the PKC activator PMA (Table 3), suggesting that its effect on
TNF-
induction by SEB is through its inhibition of PKC. These
results suggest that PTKs that are sensitive to the tyrophostin
inhibitors used in this study do not mediate SEB-induced TNF-
production in mixed cultures of monocytes and lymphocytes in which
lymphocytes are the primary producers of TNF-
. Further examination
of individual enzymes involved in signal pathways may provide
information clarifying the possible involvement of PTK activity.
 |
ACKNOWLEDGMENTS |
We thank David Hoover for his expert comments on the manuscript;
Xiaoyan Zhang, Thomas Boyle, and Peifan Sun for their help with FACScan
analysis; and Christopher Welch for his expert technical assistance in
performing proliferation assays.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Molecular Pathology, Walter Reed Army Institute of Research, Building 503, 503 Robert Grant Rd., Silver Spring, MD 20910. Phone: (301) 319-9997. Fax: (301) 319-7699. E-mail:
marti.jett{at}na.amedd.army.mil.
Present address: R. W. Johnson Pharmaceutical Research
Institute, Spring House, PA 19477.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Akatsuka, H.,
K. Imanishi,
K. Inada,
H. Yamashita,
M. Yoshida, and T. Uchiyama.
1994.
Production of tumour necrosis factors by human T cells stimulated by a superantigen, toxic shock syndrome toxin-1.
Clin. Exp. Immunol.
96:422-426[Medline].
|
| 2.
|
Albrecht, D. E., and J. G. Tidball.
1997.
Platelet-derived growth factor-stimulated secretion of basement membrane proteins by skeletal muscle occurs by tyrosine kinase-dependent and independent pathways.
J. Biol. Chem.
272:2236-2244[Abstract/Free Full Text].
|
| 3.
|
Asaoka, Y.,
M. Oka,
K. Yoshida, and Y. Nishizuka.
1991.
Metabolic rate of membrane diacylglycerol and its relation to human resting T-lymphocyte activation.
Proc. Natl. Acad. Sci. USA
88:8681-8685[Abstract/Free Full Text].
|
| 4.
|
Avery, A. C.,
J. S. Markowitz,
M. J. Grusby,
L. H. Glimcher, and H. Cantor.
1994.
Activation of T cells by superantigen in class II-negative mice.
J. Immunol.
153:4853-4861[Abstract].
|
| 5.
|
Bergdoll, M. S.
1970.
Enterotoxins, p. 265-326.
In
S. J. Ajl, T. C. Montie, and S. Kadis (ed.), Microbial toxins. Academic Press, Inc., New York, N.Y.
|
| 6.
|
Bette, J.,
M. Schafer,
K. H.,
N. Rooijen,
E. Weihe, and B. Fleischer.
1993.
Distribution and kinetics of superantigen-induced cytokine gene expression in mouse spleen.
J. Exp. Med.
178:1531-1540[Abstract/Free Full Text].
|
| 7.
|
Bleasdale, J. E.,
N. R. Thakur,
R. S. Gremban,
G. L. Bundy,
F. A. Fitzpatrick,
R. J. Smith, and S. Bunting.
1990.
Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils.
J. Pharmacol. Exp. Ther.
255:756-768[Abstract/Free Full Text].
|
| 8.
|
Bohach, G. A.,
C. V. Stauffacher,
D. H. Ohlendorf,
Y.-I. Chi,
G. M. Vath, and P. M. Schlievert.
1996.
The staphylococcal and streptococcal pyrogenic toxin family, p. 131-154.
In
B. R. Singh, and A. T. Tu (ed.), Natural toxins II. Plenum Publishing Corporation, New York, N.Y.
|
| 9.
|
Chatila, T., and R. S. Geha.
1993.
Signal transduction by microbial superantigens via MHC class II molecules.
Immunol. Rev.
131:43-59[Medline].
|
| 10.
|
Chatila, T.,
N. Wood,
J. Parsonnet, and R. S. Geha.
1988.
Toxic shock syndrome toxin-1 induces inositol phospholipid turnover, protein kinase C translocation, and calcium mobilization in human T cells.
J. Immunol.
140:1250-1255[Abstract].
|
| 11.
|
Chmura, S. J.,
H. J. Mauceri,
S. Advani,
R. Heimann,
M. A. Beckett,
E. Nodzenski,
J. Quintans,
D. W. Kufe, and R. R. Weischselbaum.
1997.
Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation.
Cancer Res.
57:4340-4347[Abstract/Free Full Text].
|
| 12.
|
de Chaffoy de Chourcelles, D.,
P. Roevens, and H. Van Belle.
1989.
The role of endogenously formed diacylglycerol in the propagation and termination of platelet activation.
J. Biol. Chem.
262:3274-3285.
|
| 13.
|
Dinarello, C. A.
1996.
Cytokines as mediators in the pathogenesis of septic shock, p. 133-165.
In
E. T. Rietschel, and H. Wagner (ed.), Pathology of septic shock, vol. 216. Springer-Verlag, Berlin, Germany.
|
| 14.
|
Elson, L. H.,
T. B. Nutman,
D. D. Metcalfe, and C. Prussin.
1995.
Flow cytometric analysis for cytokine production identifies T helper 1, T helper 2, and T helper 0 cells within the human CD4+CD27 lymphocyte subpopulation.
J. Immunol.
154:4294-4301[Abstract].
|
| 15.
|
Fischer, H.,
M. Dohlsten,
U. Andersson,
G. Hedlund,
P. Ericsson,
J. Hansson, and H. O. Sjogren.
1990.
Production of TNF-alpha and TNF-beta by staphylococcal enterotoxin A activated human T cells.
J. Immunol.
144:4663-4669[Abstract].
|
| 16.
|
Geissler, J. F.,
P. Traxler,
U. Regenass,
B. J. Murray,
J. L. Roesel,
T. Meyer,
E. McGlynn,
A. Storni, and N. B. Lydon.
1990.
Thiazolidine-diones. Biochemical and biological activity of a novel class of tyrosine protein kinase inhibitors.
J. Biol. Chem.
265:22255-22261[Abstract/Free Full Text].
|
| 17.
|
Hannun, Y. A., and R. M. Bell.
1987.
Lysosphingolipids inhibit protein kinase C: implication for the sphingolipidoses.
Science
235:670-674[Abstract/Free Full Text].
|
| 18.
|
Hardy, K., and G. Chaudhri.
1997.
Activation and signal transduction via mitogen-activated protein (MAP) kinases in T lymphocytes.
Immunol. Cell Biol.
75:528-545[Medline].
|
| 19.
|
Jardetzky, T. S.,
J. H. Brown,
J. C. Gorga,
L. J. Stern,
R. G. Urban,
Y. I. Chi,
C. Stauffacher,
J. L. Strominger, and D. C. Wiley.
1994.
Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.
Nature
368:711-718[Medline].
|
| 20.
|
Javis, W. D.,
A. J. Turner,
L. F. Povirk,
R. S. Taylor, and S. Grant.
1994.
Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C.
Cancer Res.
54:1707-1714[Abstract/Free Full Text].
|
| 21.
|
Jett, M.,
R. Neill,
C. Welch,
T. Boyle,
E. Bernton,
D. Hoover,
G. Lowell,
R. E. Hunt,
S. Chatterjee, and P. Gemski.
1994.
Identification of staphylococcal enterotoxin B sequences important for induction of lymphocyte proliferation by using synthetic peptide fragments of the toxin.
Infect. Immun.
62:3408-3415[Abstract/Free Full Text].
|
| 22.
|
Kappler, J.,
B. Kotzin,
L. Herron,
E. W. Gelfand,
R. D. Bigler,
A. Boylston,
S. Carrel,
D. N. Posnett,
Y. Choi, and P. Marrack.
1989.
V beta-specific stimulation of human T cells by staphylococcal toxins.
Science
244:811-813[Abstract/Free Full Text].
|
| 23.
|
Kappler, J. W.,
A. Herman,
J. Clements, and P. Marrack.
1992.
Mutations defining functional regions of the superantigen staphylococcal enterotoxin B.
J. Exp. Med.
175:387-396[Abstract/Free Full Text].
|
| 24.
|
Kotb, M.
1995.
Bacterial pyrogenic exotoxins as superantigens.
Clin. Microbiol. Rev.
8:411-426[Abstract].
|
| 25.
|
Li, H.,
A. Llera,
D. Tsuchiya,
L. Leder,
X. Ysern,
P. M. Schlievert,
K. Karjalainen, and R. A. Mariuzza.
1998.
Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B.
Immunity
9:807-816[Medline].
|
| 26.
|
Litton, M. J.,
B. Sander,
E. Murphy,
A. O'Garra, and J. S. Abrams.
1994.
Early expression of cytokines in lymph nodes after treatment in vivo with Staphylococcus enterotoxin B.
J. Immunol. Methods
175:47-58[Medline].
|
| 27.
|
Markovits, J.,
C. Linassier,
P. Fosse,
J. Couprie,
J. Pierre,
A. Jacquemin-Sablon,
J. Saucier,
J. Le Pecq, and A. K. Larse.
1989.
Inhibitory effects of the tyrosine kinase inhibitor genistein on mammalian DNA topoisomerase II.
Cancer Res.
49:5111-5117[Abstract/Free Full Text].
|
| 28.
|
Marrack, P.,
M. Blackman,
E. Kushnir, and J. Kappler.
1990.
The toxicity of staphylococcal enterotoxin B in mice is mediated by T cells.
J. Exp. Med.
171:455-464[Abstract/Free Full Text].
|
| 29.
|
Marrack, P., and J. Kappler.
1990.
The staphylococcal enterotoxins and their relatives.
Science
248:705-711[Abstract/Free Full Text].
|
| 30.
|
Matsuyama, S.,
Y. Koide, and T. O. Yoshida.
1993.
HLA class II molecule-mediated signal transduction mechanism responsible for the expression of interleukin-1 beta and tumor necrosis factor-alpha genes induced by a staphylococcal superantigen.
Eur. J. Immunol.
23:3194-3202[Medline].
|
| 31.
|
Mehindate, K.,
R. al-Daccak,
F. Damdoumi, and W. Mourad.
1996.
Synergistic effect between CD40 and class II signals overcomes the requirement for class II dimerization in superantigen-induced cytokine gene expression.
Eur. J. Immunol.
26:2075-2080[Medline].
|
| 32.
|
Miethke, T.,
C. Wahl,
K. Heeg,
B. Echtenacher,
P. H. Krammer, and H. Wagner.
1993.
Superantigen mediated shock: a cytokine release syndrome.
Immunobiology
189:270-284[Medline].
|
| 33.
|
Miethke, T.,
C. Wahl,
K. Heeg,
B. Echtenacher,
P. H. Krammer, and H. Wagner.
1992.
T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor.
J. Exp. Med.
175:91-98[Abstract/Free Full Text].
|
| 34.
|
Morio, T.,
R. S. Geha, and T. A. Chatila.
1994.
Engagement of MHC class II molecules by staphylococcal superantigens activates src-type protein tyrosine kinases.
Eur. J. Immunol.
24:651-658[Medline].
|
| 35.
|
Neill, R. J.,
M. Jett,
R. Crane,
J. Wootres,
C. Welch,
D. Hoover, and P. Gemski.
1996.
Mitogenic activities of amino acid substitution mutants of staphylococcal enterotoxin B in human and mouse lymphocyte cultures.
Infect. Immun.
64:3007-3015[Abstract].
|
| 36.
|
Nishizuka, Y.
1992.
Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C.
Science
258:607-614[Abstract/Free Full Text].
|
| 37.
|
Novogrodsky, A.,
A. Vanichkin,
M. Patya,
A. Gazit,
N. Osherov, and A. Levitzki.
1994.
Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors.
Science
264:1319-1322[Abstract/Free Full Text].
|
| 38.
|
Palkama, T., and M. Hurme.
1993.
Signal transduction mechanisms of HLA-DR-mediated interleukin-1 beta production in human monocytes. Role of protein kinase C and tyrosine kinase activation.
Hum. Immunol.
36:259-267[Medline].
|
| 39.
|
Schlievert, P. M.
1993.
Role of superantigens in human disease.
J. Infect. Dis.
167:997-1002[Medline].
|
| 40.
|
Scholl, P. R.,
N. Trede,
T. A. Chatila, and R. S. Geha.
1992.
Role of protein tyrosine phosphorylation in monokine induction by the staphylococcal superantigen toxic shock syndrome toxin-1.
J. Immunol.
148:2237-2241[Abstract].
|
| 41.
|
See, R. H., and A. W. Chow.
1992.
Staphylococcal toxic shock syndrome toxin 1-induced tumor necrosis factor alpha and interleukin-1 secretion by human peripheral blood monocytes and T lymphocytes is differentially suppressed by protein kinase inhibitors.
Infect. Immun.
60:3456-3459[Abstract/Free Full Text].
|
| 42.
|
See, R. H.,
W. W. Kum,
A. H. Chang,
S. H. Goh, and A. W. Chow.
1992.
Induction of tumor necrosis factor and interleukin-1 by purified staphylococcal toxic shock syndrome toxin 1 requires the presence of both monocytes and T lymphocytes.
Infect. Immun.
60:2612-2618[Abstract/Free Full Text].
|
| 43.
|
Trede, N. S.,
R. S. Geha, and T. Chatila.
1991.
Transcriptional activation of IL-1 beta and tumor necrosis factor-alpha genes by MHC class II ligands.
J. Immunol.
146:2310-2315[Abstract].
|
| 44.
|
Trede, N. S.,
T. Morio,
P. R. Scholl,
R. S. Geha, and T. Chatila.
1994.
Early activation events induced by the staphylococcal superantigen toxic shock syndrome toxin-1 in human peripheral blood monocytes.
Clin. Immunol. Immunopathol.
70:137-144[Medline].
|
| 45.
|
Xiao, G.,
K. C. Falkner,
Y. Xie,
R. G. Lindahl, and R. A. Prough.
1997.
cAMP-dependent negative regulation of rat aldehyde dehydrogenase class 3 gene expression.
J. Biol. Chem.
272:3238-3245[Abstract/Free Full Text].
|
| 46.
|
Yeung, R. S.,
J. M. Penninger,
T. Kundig,
W. Khoo,
P. S. Ohashi,
G. Kroemer, and T. W. Mak.
1996.
Human CD4 and human major histocompatibility complex class II (DQ6) transgenic mice: supersensitivity to superantigen-induced septic shock.
Eur. J. Immunol.
26:1074-1082[Medline].
|
Infection and Immunity, December 1999, p. 6611-6618, Vol. 67, No. 12
0019-9567/99/$04.00+0
This article has been cited by other articles:
-
Ogata, M., Nandate, K., Kawasaki, T., Kawasaki, C., Ozaki, M., Shigematsu, A.
(2004). A Platelet Activating Factor Receptor Antagonist Inhibits Cytokine Production in Human Whole Blood by Bacterial Toxins and Live Bacteria. Anesth. Analg.
98: 1767-1772
[Abstract]
[Full Text]
-
Wang, D., Pedraza, P. L., Abdullah, H. I., McGiff, J. C., Ferreri, N. R.
(2002). Calcium-sensing receptor-mediated TNF production in medullary thick ascending limb cells. Am. J. Physiol. Renal Physiol.
283: F963-F970
[Abstract]
[Full Text]
-
Kawasaki, C., Kawasaki, T., Ogata, M., Nandate, K., Shigematsu, A.
(2001). Ketamine isomers suppress superantigen-induced proinflammatory cytokine production in human whole blood : [Les isomeres de la ketamine suppriment la production de cytokine pro-inflammatoire induite par des superantigenes dans le sang complet humain]. Canadian J. Anesthesia
48: 819-823
[Abstract]
[Full Text]
-
Komisar, J. L., Weng, C.-F., Oyejide, A., Hunt, R. E., Briscoe, C., Tseng, J.
(2001). Cellular and Cytokine Responses in the Circulation and Tissue Reactions in the Lung of Rhesus Monkeys (Macaca mulatta) Pretreated with Cyclosporin A and Challenged with Staphylococcal Enterotoxin B. Toxicol Pathol
29: 369-378
[Abstract]